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The formalin-fixed, paraffin-embedded (FFPE) biopsy is a challenging sample for molecular assays such as targeted
next-generation sequencing (NGS). We compared three methods for FFPE DNA quantification, including a novel
PCR assay (‘QFI-PCR’) that measures the absolute copy number of amplifiable DNA, across 165 residual clinical
specimens. The results reveal the limitations of commonly used approaches, and demonstrate the value of an
integrated workflow using QFI-PCR to improve the accuracy of NGS mutation detection and guide changes in input
that can rescue low quality FFPE DNA. These findings address a growing need for improved quality measures in
NGS-based patient testing.Background
Approximately 120 years ago, formaldehyde was identi-
fied as a superior fixation agent to preserve tissue sam-
ples [1]. Since that time, preservation of tissues with
formalin-fixed paraffin-embedding (FFPE) procedures
has emerged as the method of choice for histological
study and archival storage of clinical specimens. More
than 400 million FFPE samples are thought to exist and
many have clinical annotations such as primary diagno-
sis, therapeutic regimen, drug response, and recurrence
status. These archives represent an invaluable repository
of retrospective patient clinical data. Powerful new gen-
omic technologies, such as next-generation sequencing
(NGS), promise to unlock the molecular features of such
samples and inform the linkage of genotype and pheno-
type. Achievement of this goal requires that the unin-
tended consequences of the fixation and embedding
process and the duration and conditions of storage on
nucleic acid quality be accommodated by the profiling
methodology to ensure reliable, accurate, and sensitive
biomarker detection.* Correspondence: glatham@asuragen.com
Asuragen, Inc, Austin, TX 78744, USA
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reproduction in any medium, provided the orUnfortunately, the FFPE process causes fragmentation
and chemical modifications in DNA, such as cross-linking,
deamination and adducts [2-4]. These modifications re-
duce the number of DNA templates available for amplifi-
cation, and pose significant challenges to efficient PCR.
Factors such as type of fixative, fixation time, age and stor-
age conditions of the FFPE block can contribute to prob-
lems in diagnostic testing [5]. In light of these challenges,
pre-analytical methods such as end-point PCR using dif-
ferent reference gene amplicon lengths have been previ-
ously described to help qualify samples for molecular
methods downstream [6-8].
Two common methods for DNA quantification are
spectrophotometry and fluorometry using DNA-binding
dyes. Spectrophotometry offers a simple and nimble
way to accurately measure the bulk concentration of high
quality DNA and instruments such as the NanoDrop
Spectophotometer are readily available. Yet spectropho-
tometry cannot gauge the molecular damage and fragmen-
tation caused by fixation, embedding, and/or long-term
storage, nor can it anticipate the effects on PCR. For ex-
ample, a recent study comparing the accuracy of different
methods to quantify DNA following controlled degrad-
ation demonstrated up to a three-fold difference between. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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fragments of 150 bp; DNA quantification by PCR, but not
spectrophotometry, was affected by the extent of DNA
shearing [9]. Spectrophotometry is also susceptible to erro-
neous measurements from contaminants like RNA and
other organic solvents, such as phenol, used in DNA ex-
traction. Fluorometric DNA quantification methods, such
as the Qubit® assay, offer high analytical sensitivity, high
throughput, and improved tolerance to contaminants. As
such, an increasing number of laboratories have adopted
this approach as a best practice for NGS applications [10].
Limitations in the availability of many clinical speci-
mens drive the need for low DNA inputs into molecular
assays. Cutting edge technologies such as NGS can push
the boundaries of input DNA material required for in-
depth molecular profiling, particularly in cancer [11-14].
FFPE tumor DNA presents a dual challenge for muta-
tion testing, namely requirements for low template input
quantities combined with template damage from the fix-
ation and embedding process that resist amplification by
PCR. In addition, low quality FFPE DNA can trigger al-
lele dropouts and produce inaccurate results [6,15]. As a
result, metrics based on sensitive and quantitative pre-
analytical sample characterization are needed to assess
the fraction of template molecules that are competent
for PCR amplification.
The goal of this study was to establish and integrate
quantitative, pre-analytical molecular quality assessments
of FFPE DNA with targeted NGS data to ensure accurate
and reliable data interpretations. The approach that we
describe, which includes the use of an optimized qPCR
assay termed quantitative functional index (QFI)-PCR, le-
verages broadly available instrumentation (that is, a real-
time thermal cycler) and quantifies the absolute number
of amplifiable templates in a FFPE DNA sample. Import-
antly, the strategy is designed to quantify amplicons that
are of a similar size as those in the target PCR enrichment
library to tightly link functional copy numbers determined
in the pre-analytical phase to the performance characteris-
tics of amplicon libraries generated in the ensuing analyt-
ical phase. Our findings underscore the influence of FFPE
DNA quality on NGS results and interpretations and pre-
scribe sample-specific, data-driven metrics that can ac-
commodate the analysis of low quality DNA in diagnostic
cancer applications. This guidance is timely given the
rapid migration of NGS into clinical test settings.
Methods
Study design
The study was designed first to benchmark different
methods for pre-analytical FFPE sample characterization
and then to synthesize the most informative analyses
with the results of targeted NGS-based variant calling
(Figure 1). In the initial phase of the study, FFPE DNAassessments determined by spectrophotometry, a sensitive
and commonly used fluorescent dye assay (Qubit), and a
novel qPCR assay (QFI-PCR) were compared across 165
residual clinical FFPE samples. Quantitative measures of
DNA template quality determined by QFI-PCR were then
compared with targeted NGS results using defined metrics
across varying ‘functional’ FFPE DNA copy numbers to
demonstrate DNA quality and input thresholds that sup-
ported accurate variant calling. The predictive value of
QFI-PCR-based thresholds was established in a titration
study, and then applied to a set of 44 FFPE DNA
samples interrogated with the Ion AmpliSeq™ Cancer
Panel, a commercially available, highly multiplexed PCR
method that enriches loci in 46 cancer genes for NGS on
the Ion Torrent Personal Genome Machine (PGM; Life
Technologies, Carlsbad, CA, USA).
FFPE specimens and DNA controls
The 165 specimens used in this study were obtained as
FFPE blocks from three different sources. Fifty samples
that had >70% tumor content and <20% necrosis were
selected from Asuragen’s FFPE tumor database. This set
included 10 samples each from colon, lung, skin, ovary,
and breast tumor biopsies. Seventy-six FFPE blocks
containing thyroid tumor biopsies were purchased from
Asterand (Detroit, MI, USA). The remaining 39 FFPE
tissue specimens were processed from colorectal cancer
resections purchased from Folio Biosciences (Columbus,
OH, USA) [14]. The ages of the FFPE blocks across all
three cohorts ranged from 1 to 18 years. The mean DNA
functional quality (QFI; see below) for the Asuragen,
Asterand and Folio Biosciences cohorts was 8.0 (95% con-
fidence interval (CI) 6.3 to 9.7), 6.0 (95% CI 4.3 to 7.7) and
3.5 (95% CI 2.1 to 4.9), respectively. No significant dif-
ference in the QFI was observed as a function of the
age of the FFPE block. All samples were residual de-
identified samples acquired in accordance with appro-
priate human subjects’ regulations using an institutional
review board-approved protocol. In addition, Asuragen
has filed a Federalwide Assurance for the Protection of
Human Subjects (FWA) with the US Department of
Health and Human Services.
DNA for all samples was isolated using a modification of
the RecoverAll™ Total Nucleic Acid Isolation Kit for FFPE
(Life Technologies) [14]. Poor quality samples produced a
similar DNA yield and quality following re-extraction. Cell
line NA04025 DNA was used as the DNA calibrator for
qPCR (NIGMS Human Genetic Cell Repository, Coriell
Institute, Camden, NJ, USA).
DNA copy number quantification using QFI-PCR
DNA samples were initially quantified using NanoDrop
spectrophotometer (ThermoScientific, Wilmington, DE,
USA) and normalized to 10 ng/μl in deionized water.
165 Residual Clinical FFPE Tumors
• 6 different tumor types
• 3 distinct collection cohorts 
• Isolate DNA 






































Figure 1 Study design. The study design coupled pre-analytical FFPE DNA characterization across three methods (spectrophotometry,
fluorescence dye-based quantification, and QFI-PCR) with variant calling results from targeted NGS and confirmation assays to assess the impact
of template quality and set thresholds for minimum ‘functional’ DNA inputs. dsDNA, double-stranded DNA; HS, high sensitivity.
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using qPCR on a 7900HT Fast Real-Time PCR System
(Life Technologies). Quantification of amplifiable DNA
was assessed by amplifying a 119 bp region in the TATA
box binding protein gene (TBP). The amplicon length
was specifically designed to represent the 120 bp average
amplicon size generated for the AmpliSeq™ Cancer Panel.
qPCR was carried out in 11 μl reactions with 1× Taqman®
Gene Expression Master Mix (Life Technologies), 900 nM
forward primer (5′-CCA GAC TGG CAG CAA GAA
AAT-3′; Integrated DNA Technologies, Coralville, IA,
USA), 900 nM reverse primer (5′-CCT TAT AGG
AAA CTT CAC ATC ACA GC-3′; Integrated DNA
Technologies), 250 nM Taqman® probe (5′-VIC-TGC
TAG AGT TGT ACA GAA GTT GGG TTT TCC AGC-
TAMRA-3′; Life Technologies) and 5 ng of DNA. A sec-
ond qPCR assay (900 nM forward primer 5′-CCT CTG
CCT CCG GCA TTT-3′, 900 nM reverse primer 5′-GCC
CCC AAG GTT TGC TAT TC-3′, 250 nM probe 5′ 6-
FAM/ZEN/3′IB®FQ-CCA GCG TTT TTT GCT TAG
GTA TCC AGC TCC-3′; Integrated DNA Technologies),
was designed on the ferritin, heavy polypeptide 1 (FTH1)
gene and also targeted a 119 bp region. The PCR cyc-
ling conditions were 95°C for 10 minutes, 50 cycles
of 95°C for 15 s, and 60°C for 1 minute. A calibration
curve was generated using data from PCR amplifica-
tion of high quality genomic DNA extracted from the
cell line NA04025 (Coriell Cell Repositories, Camden,NJ, USA) using a 5-fold titration series, from 50 ng to 16
pg (15,150 to 5 copies). Copy number - a measure of PCR
competency and template ‘functionality’ - was then calcu-
lated from the calibration curve. We note that it is critic-
ally important to enlist a high quality DNA as a standard
to generate the calibration curve since this DNA serves as
a reference for a ‘100% functional’ template.
In this study, ‘functionality’ is synonymous with the
QFI and is defined as the fraction of haploid DNA tem-
plates available for amplification compared to the cali-
brator DNA standard curve. For example, a sample with
an input of 10 ng into the qPCR would have a QFI of
100% if all 3,030 haploid templates were available for
amplification. Similarly, the QFI would be 3.3% if only
100 of the 3,030 input template copies could be ampli-
fied to generate the target amplicon.
DNA quantification using the Qubit® 2.0 Fluorometer
A total of 165 FFPE samples were diluted to 5 ng/μl and
quantified using the Qubit dsDNA HS Assay Kit (cata-
logue number Q32854, Life Technologies) and the Qubit
2.0 Fluorometer (Life Technologies) per the manufac-
turer’s instruction. Briefly, 1 μl of DNA sample at 5 ng/μl
was diluted 200-fold in Qubit dsDNA HS buffer in clear
plastic Qubit Assay Tubes (catalogue number Q32856,
Life Technologies) and measured on the fluorometer.
Prior to taking the measurements, a two-point calibration
curve was established using the supplied standards with
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the limit of quantification of 0.5 ng/ml (0.1 ng/μl, diluted
200-fold) were not reported by Qubit.
‘SPUD’ inhibition assay
To evaluate any PCR inhibition, 32 samples that spanned
the spectrum of quality as assessed by QFI-PCR were ana-
lyzed using the ‘SPUD’ assay, as described by Nolan et al.
[16] (Additional file 1). This assay is specific for potato
(Solanum tuberosum) and lacks homology with human
DNA. In this assay, PCR inhibition is revealed by a change
in the quantification cycle (Cq) value and is indicative of
inhibitors in the sample tested. The PCR cycling condi-
tions were 95°C for 10 minutes, 50 cycles of 95°C for 15 s,
and 60°C for 1 minute.
Titration of FFPE functional copy number and MiSeq
sequencing
To investigate the impact of limiting the FFPE DNA in-
put on mutation calling, a dilution series of two well
characterized FFPE DNA samples was created. Sample A
was a residual clinical colon FFPE sample with a BRAF
V600E mutation determined at a NGS read frequency of
30.0 ± 3.4% across 19 independent targeted NGS runs,
using a combination of an internally developed PCR-
based enrichment panel (SuraSeq™, Asuragen) [14] and
the Ion AmpliSeq Cancer Panel and sequenced on the
PGM. Sample B was also a colon FFPE tumor resection,
but contained a known PIK3CA H1047R variant present
at 38.4 ± 4.6%, averaged across six NGS runs using the
same methodologies. For both samples A and B, the muta-
tions were sequenced at a median read depth of >3,000×
in all runs. Each of these DNA samples revealed a QFI of
9%. DNA from these FFPE samples was used to generate a
2-fold dilution series from 10 ng to 78 pg (3,030 to 24
haploid DNA copies; Additional file 2), and amplified
using targeted NGS as described in Hadd et al. [14]. Each
sample (titration point) was then tagged with a unique
barcode and sequenced on the MiSeq (Illumina, San
Diego, CA, USA).
AmpliSeq cancer panel enrichment, PGM sequencing,
and Torrent Server plugin variant analysis
Forty-four FFPE samples spanning the spectrum of DNA
quality (as determined by the QFI-PCR) were enriched
for 190 amplicons using the Ion AmpliSeq Cancer Panel,
barcoded, and sequenced on the Ion Torrent PGM, per
the supplier’s instructions. Briefly, 10 ng of DNA (as
measured by Nanodrop spectrophotometer) was ampli-
fied using the supplied reagents for 20 cycles. PCR prod-
ucts were ligated with barcodes and re-amplified for
seven cycles, purified, quantified with a BioAnalyzer
2100 (Agilent, Santa Clara, CA, USA) and normalized.
Samples were then pooled into 4 tubes, each containing10 to 12 samples. Each sample was diluted using nucle-
ase free water and 100 million copies were used in the
emulsion PCR reaction using Ion OneTouch™ (Life
Technologies). Template-positive ion sphere particles
were enriched using the Ion OneTouch™ ES system (Life
Technologies) and subsequently sequenced on an Ion
Torrent PGM following the manufacturer’s recommen-
dation on four 318 chips. Raw sequence data are available
for download through the NCBI under the following ac-
cession ID: PRJNA212586 [17].
All data analysis was performed using the Torrent
Suite v3.2.1 (Life Technologies). Samples were automat-
ically split using pre-defined barcodes and reads were
aligned to the reference human genome hg19. Variant
calling was performed using the plugin v3.2.4. Over 99%
of all variants reported by the plugin had at least 100
reads (median = 920 reads). Less than 1% of all detected
variants were reported as indels by the Torrent plugin.
As a confirmation strategy, the same set of 44 FFPE
samples was also processed using an internally devel-
oped 16 gene PCR enrichment panel [14] and sequenced
on the PGM. Variant calling on the 16 gene panel was
performed as previously described in Hadd et al. [14].
All reported variants from the 16 gene panel were cov-
ered by at least 200 reads (median = 5,881 reads). No
indel variants detected in the primary AmpliSeq assay
overlapped with the region sequenced using the 16 gene
confirmation panel. As a result, none of these indels
could be confirmed.
Results
Variability of FFPE DNA quantification across three
methods
In our initial studies assessing targeted NGS of tumor
FFPE DNA, we observed that DNA quantification varied
significantly across spectrophotometric, fluorescent, and
qPCR-based assays. This result is clearly shown in Figure 2A,
where 5 ng of residual clinical FFPE DNA determined
spectrophotometrically (NanoDrop) produced extremely
variable results compared to a widely used DNA-binding
fluorescent dye assay (Qubit). For example, when three
distinct FFPE sample cohorts representing 165 specimens
were standardized to 5 ng DNA, the Qubit assay reported
a median of 0.30 ± 0.4 ng (interquartile range 0.13 to
0.49). Thus, the NanoDrop reported an approximately 17-
fold higher DNA concentration in these FFPE DNA
specimens.
In addition to spectrophotometry and Qubit, we also
evaluated a qPCR-based assay. Unlike the Qubit assay,
qPCR offers an unforgiving and strict requirement for
template quality; chemically modified or fragmented
DNA strands that cannot be amplified simply drop out
during PCR and failed to report a signal, just as they
would during PCR-based target enrichment for NGS. To
N=133 N=155



































Figure 2 FFPE DNA characterization by QFI-PCR and fluorescence-based assays from 165 tumor DNA samples. (A) Distribution of FFPE
DNA quantification using QFI-PCR and the fluorescence-based Qubit dsDNA HS assay from 5 ng bulk DNA input as determined by NanoDrop
spectrophotometry. A total of 27 samples were undetected by fluorescence assay (<0.1 ng/μl, equivalent to 2% ‘functional’ DNA templates;
shown as open circles); these samples produced between 0.03 and 2.5% QFI using qPCR. Five samples were undetected by QFI-PCR and
produced between 2.4 to 4.0% of the spectrophotometrically determined DNA concentration using Qubit. Five samples were undetected using
both methods (not shown in figure). (B) A scatterplot of QFI-PCR and Qubit relative DNA quantification revealed a linear trend for templates
with at least 3% QFI (R = 0.66; N = 86). No correlation, however, was observed for the poorest quality samples (R = 0.07; N = 42; shown as
open circles).
Sah et al. Genome Medicine 2013, 5:77 Page 5 of 12
http://genomemedicine.com/content/5/8/77enable a simple, economical, and high throughput assay
configuration, we selected a single locus for PCR in the
TBP gene, chosen because it is devoid of widespread
gene amplification or deletion events in cancer. For ex-
ample, an analysis of copy number changes reported
through the cBioPortal for Cancer Genomics revealed an
average of 0.8% and 0.4% of samples with deletion or
amplification events, respectively, in the TBP gene across
the 6 cancer types tested in this study [18,19]. Import-
antly, the amplicon length for this qPCR assay was
designed to be 119 bp, or equivalent to the median
length of amplicons produced for the associated NGS
studies.
The qPCR assay, termed QFI-PCR, was calibrated to
high quality cell line DNA (NA04025). QFI-PCR was effi-
cient, sensitive, and repeatable. For example, the PCR
amplification efficiency of this assay over four independent
runs was 92.6 ± 4.5%. The limit of detection was 5 copies
of target, and the limit of quantification was 10 copies
(using a criterion of <0.5 standard deviation in Cq variabil-
ity). Thus, the assay can quantify as few as 10 DNA copies,
which would correspond to 0.67% amplifiable templates
in a background of 5 ng genomic DNA (equivalent to
1,515 haploid copies total input). In repeatability ex-
periments, a mean coefficient of variation (CV) of 26%(95% CI 21.8 to 30.4%) was observed in 3 independent
runs with 2 operators, determined across 43 FFPE DNA
samples.
For a target FFPE DNA sample, 5 ng of template (nom-
inally determined by NanoDrop) was input into QFI-PCR,
and the Cq output was converted to a ‘functional’ copy
number. The ratio of the calculated sample DNA copy
number to the referenced calibrator DNA copy number at
the same mass input revealed the fraction of sample tem-
plates that were competent for PCR amplification. This
fraction, expressed as a percentage, represented the per-
centage of functional templates, or QFI.
Of the 165 FFPE DNA samples tested using QFI-PCR,
155 (93.9%) yielded a detectable Cq value, whereas 10
(6.1%) samples were undetected at 50 cycles. The mea-
sured QFI for the detected samples ranged from 0.03 to
24.5%, and the median value was 3.96% (interquartile range
1.22 to 8.55%). A PCR inhibition assay [16], performed on
a subset of 32 samples that spanned the range of FFPE
DNA quality, showed no signs of inhibition (<1 Cq shift),
suggesting that samples with low QFI were indeed a conse-
quence of poor DNA integrity (Additional file 1).
In contrast to QFI-PCR, three times as many DNA sam-
ples (32, or 19.4%) failed to report a value above the back-
ground of the Qubit assay. Moreover, five of these DNA
Sah et al. Genome Medicine 2013, 5:77 Page 6 of 12
http://genomemedicine.com/content/5/8/77samples were also null in the qPCR assay; these samples
represented one-half of the total PCR-negatives. A
scatterplot of QFI-PCR and Qubit DNA template func-
tionality (Figure 2B) revealed a linear trend for templates
with at least 3% QFI by qPCR (R = 0.66; N = 86). No cor-
relation, however, was observed for the poorest quality
samples (<3% QFI). The 79 samples within this group
reported a median of 2.6% relative quantification (range
0.0 to 8.8%) using the Qubit assay, but a median QFI of
only 0.78% (range 0.0 to 2.86%), suggesting that these
samples were highly degraded with little to no amplifiable
DNA present.
Similar QFI scores were obtained using a subset of 62
FFPE samples, including at least 7 for each of the 6 can-
cer types, when the quality was assessed with an alterna-
tive gene, FTH1, to TBP. The average fold change between
the two genes was 1.01 (95% CI 0.8 to 1.04), and no sam-
ples with a QFI >3% showed more than a two-fold differ-
ence (Additional file 3).
Impact of defined FFPE DNA copy number on NGS variant
quantification
We hypothesized that the low QFI associated with many
FFPE samples would have an adverse impact on mutation
calling in NGS assays. For example, the recommended
DNA input into the Ion AmpliSeq™ Cancer Panel - a com-
mercial enrichment method for targeting diagnostically
relevant sequences across 46 cancer-associated genes - is
only 10 ng. This input corresponds to 3,030 haploid copies
of genomic DNA. The number of amplifiable templates in
10 ng of FFPE DNA can readily be calculated from the
QFI. For example, the QFI was 1.2% for the 25th percentile
FFPE DNA samples with a detectable Cq, which corre-
sponds to 0.012 × 3,030 = 36 amplifiable templates. If 10
mutant template copies are needed for accurate percent-
age variant calling by NGS, then one would expect that
FFPE specimens with 1.2% QFI would require a minimum
of 27.8% (10/36) mutant templates to be reliably quanti-
fied. As a result, the risk of false negative results may be
elevated in low quality FFPE DNA due to the paucity of
amplifiable templates.
To test this hypothesis, we performed a dilution series
of FFPE DNA samples for which the oncogene muta-
tions, mutational load, and QFI had been well character-
ized. Residual colon tumor FFPE specimens with BRAF
V600E or PIK3CA H1047R mutations were independ-
ently diluted in two-fold decrements. The percentage of
mutation was determined for each sample prior to dilu-
tion by either 19 or 6 independent targeted NGS runs,
with results of 30.0 ± 3.4% BRAF V600E and 38.4 ±
4.6% PIK3CA H1047R, respectively [14]. We selected 10
mutant allele copies as a minimum number required for
accurate quantification to minimize stochastic fluctua-
tions in the variant representation. Consequently, wecalculated that 33.3 haploid copies (10/0.30) and 26.0
haploid copies (10/0.384) are required to reliably quan-
tify the 30.0% BRAF and 38.4% PIK3CA mutations, re-
spectively. This copy number requirement, however,
increased by more than an order of magnitude when the
QFI (9% for both samples) was considered. When this
value was factored in, a total of 370 copies (33.3/0.09) of
the BRAF V600E sample, and 289 copies (26.0/0.09) of
the PIK3CA H1047R sample, were determined to be ne-
cessary to accurately quantify the underlying mutations.
The results of the titration series revealed that the
detected mutation fraction was highly variable in both
samples when the template input was less than 379 copies
(Figure 3). For example, at or below 189 template copies,
a CV of 125% and 43% for quantification of the BRAF and
PIK3CA mutations, respectively, was observed. This vari-
ation stabilized to a CV of 6% and 14% for the same two
mutations when the input was increased to 379 copies.
The result was in excellent agreement with the theoretical
copy number input calculation. Most strikingly, the BRAF
V600E mutation was present in <6% of NGS reads when
the template was input at 24 and 95 copies. This level of
detection is at or below the level of reliable calling from
recent published studies of targeted NGS in FFPE DNA
[14,20], suggesting a high probability of a false negative.
Nearly 65% of the samples in our 165 specimen cohort
had a QFI <6.6%. At this quality threshold, a 10 ng input
would correspond to only 200 copies of template. This
copy number is approximately the minimum required to
accurately quantify a mutation present in 5% of tem-
plates when the output is not limited by the NGS read
depth. The large fraction of samples in our cohort with this
poor quality underscores the importance of understanding
the sample-specific DNA characteristics to ensure accurate
downstream NGS interpretation. For example, an increase
in copy number may be achieved for samples with a bor-
derline QFI relative to variant call sensitivity. If the follow-
ing formula is used to calculate the bulk DNA input mass
into PCR to achieve the reliable quantification of %M
mutation:
Bulk DNA input ngð Þ ¼ 10
303  QFI %Mð Þ
where the DNA input is expressed in nanograms (bulk
DNA mass by spectrophotometry), 303 is the number of
haploid copies per 1 ng of DNA, and the QFI is the quanti-
tative functional index, then FFPE DNA inputs may be ad-
justed accordingly to ensure appropriate library complexity.
Impact of FFPE DNA quality on NGS false positive calls
Having established the predictive value of a QFI threshold
to ensure accurate variant quantification and minimize
the risk of false negatives, we next explored the impact of
CV= 125% CV= 6% CV= 43% CV= 14%
24      47      95      189    379   758   1515  3030   24      47      95 189    379   758  1515  3030


















Figure 3 Effect of amplifiable FFPE DNA copy number on the detection of mutational load by targeted NGS. The amplifiable DNA copy
number (Cp#) for two clinical FFPE samples was calculated to be 370 and 289 copies based on the QFI (9% for both samples) and a well-characterized
mutation frequency of 30.0 ± 3.4% for BRAF V600E or 38.4 ± 4.6% for PIK3CA H1047R, respectively. BRAF and PIK3CA loci were enriched using PCR [14]
and sequenced on the MiSeq. The graph shows a dilution series of the DNA, from 24 to 3,030 amplifiable DNA copies and each point (blue, BRAF; red,
PIK3CA) represents the fraction of reads with the target mutation.
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AmpliSeq Cancer Panel [20]. This panel was selected be-
cause of its widespread use, and claims to support FFPE
DNA inputs (for example, 10 ng) that may be vulnerable
to erroneous mutation calls when low quality FFPE DNA
samples are used. Forty-four FFPE DNA samples were
enriched across 46 genes and sequenced on the PGM.
More than 20 million total reads were generated over four
318 chips with a median of 419,656 reads per sample. The
median read depth across all samples was 2,301 and the
median C100 (the fraction of bases with at least 100×
coverage) was 99.7%. All controls, including FFPE samples
that had been previously characterized using an independ-
ent NGS method [14], produced the expected results.
Analyses of the data revealed an inverse relationship
between the QFI and the number of variants detected
using the AmpliSeq assay. Samples with a low QFI (that
is, functionality of less than 3 to 6%, or about 100 to 200
copies of amplifiable template at 10 ng input) produced
a significantly larger number of variants from AmpliSeq
NGS compared to those with >6% functionality (P-value
0.006, unequal variance) (Figure 4). In fact, >95 variants
each were associated with 6 of these low quality DNA
samples, of which >75% of the sample-specific variants
were detected with a mutation frequency of <10%. Acomparison of the mutation frequency among three sam-
ples each from the lowest and highest QFI categories is
shown in Additional file 4. Since the AmpliSeq Cancer
Panel interrogates a 13 kb region of interest, each DNA
sample would be expected to present approximately 13
SNPs, based on an incidence of 1 SNP per 1,000 bases
[21]. Consistent with this estimate, the mean number of
variants for samples with QFI >6% was 14.7 ± 5.8. The
mean number of variants for samples with QFI <3%, how-
ever, was 166.0 ± 161, suggesting that approximately 90%
of the reported variants were false positives.
We next sought to confirm the suspicion of an inflated
false positive call rate for the lowest quality FFPE DNA
samples. All 44 FFPE samples were analyzed using an in-
ternally developed, 16 oncogene PCR enrichment panel
that was orthogonal to the AmpliSeq Cancer Panel meth-
odology, sequenced on the PGM, and profiled using a pre-
viously described algorithm [14]. Compared to both
Sanger sequencing and a high sensitivity liquid bead array
method, this targeted NGS method demonstrated excel-
lent concordance in FFPE DNA, and analytical sensitivity
to 4% variant [14]. Only those variants from the AmpliSeq
Cancer Panel that overlapped with the internal panel con-
tent were considered for analysis. Representative samples




















<6%                      >6%
QFI
Figure 4 Effect of FFPE DNA copy number on NGS variant calling using a commercial targeted enrichment cancer panel. A) Correlation
between QFI and number of variants detected on the PGM following enrichment using the AmpliSeq Cancer Panel. (B) Samples with the lowest
QFI produced a significantly larger number of variants from AmpliSeq NGS compared to those with >6% QFI (P-value 0.006).
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<3%, all 5 samples with QFI between 6 and 7%, and the 6
samples with the highest QFI.
From the primary, unfiltered analysis, only 13% (26/199)
of the positives detected by AmpliSeq NGS for samples
with <3% QFI could be confirmed (Table 1). At least three
categories of false positives were present: i) systematic
positives in the PIK3CA locus that were present in both
high and low quality FFPE samples; ii) low abundance
variant calls that were below the threshold of the NGS-
based confirmation assay (that is, <4%); and iii) positive
calls that were within the range of analytical sensitivity of
the confirmation assay (that is, ≥4%). To ensure maximum
relevance in the final results, only variants with >5% mean
allele frequency from AmpliSeq NGS were evaluated for
the calculation of true positives, and systemic variants
in the PIK3CA gene were excluded. Even after the
use of these filters, only 44% of the detected variants
could be confirmed for samples with <3% QFI. In con-
trast, 90% and 96% of variants were confirmed with sam-
ples that had 6 to 7% and at least 16.5% QFI, respectively
(Additional file 5). KRAS codon 12/13 positives were
further confirmed using a second method (liquid bead
array) [22], which agreed with the results of confirmation
sequencing for the common mutations. As a result, a
threshold of 3 to 6% QFI clearly distinguished expected
from artificially inflated variant populations and offered a
benchmark to support accuracy in variant calling. This
threshold is also well matched to ab initio calculations of
template library complexity relevant to low-level mutation
calling in tumor specimens.
Discussion
As NGS technologies advance into clinical settings, it is
critical to establish quality control metrics that can guidereliable sequencing results. To this end, entities such as the
Next-generation Sequencing Standardization of Clinical
Testing (Nex-StoCT) workgroup (coordinated by the
Centers for Disease Control), and the College of American
Pathologists have proposed criteria for assuring quality
NGS data and interpretations. For example, Nex-StoCT
recommended a series of post-analytical quality control
metrics relevant to NGS, including depth and uniformity
of coverage, transition/transversion ratio, base call quality
score, mapping quality, and others [23]. Pre-analytical
quality control metrics, such as determining the minimum
DNA requirements needed to perform the test, are also
critical. Although DNA characterization using spectro-
photometry is appropriate for many molecular tests
and specimen types, FFPE DNA samples pose unique
challenges, particularly for amplification-based assays.
Targeted detection of FFPE DNA analytes by NGS, a
method that offers true digital quantification, demands a
careful consideration of template library complexity to
achieve reliable and accurate results.
In this study, we compared three assays for assessing
FFPE DNA inputs into targeted NGS. The first was
spectrophotometry, a method that only reports the ‘bulk’
DNA concentration. Compared to the other quantification
methods, this approach overestimated the ‘functional’
DNA concentration by approximately 15-fold across 165
FFPE DNA samples. As a result, we can conclude that
spectrophotometry is inappropriate to determine FFPE
DNA inputs into PCR-based NGS enrichment since it
provides no information to ensure accurate results with
both low and high quality DNA samples.
The second comparator method was a fluorescent dye-
binding assay (Qubit). This assay is widely used, and offers
simplicity, sensitivity, high throughput, and tolerance
to various contaminants. Interestingly, we find that







































RS00863 Low 0.5 4 451 48 44 28 3 10.7 2 BRAF V600E 23.8%
RS00856 Low 0.7 5 352 42 36 26 3 11.5 2 KRAS G13C 29.0%
RS01279 Low 1.1 4 123 23 19 8 3 37.5 3 None
RS00865 Low 2.2 4 222 33 30 21 3 14.3 2 NRAS G12R 23.0%
RS01283 Low 2.3 0 31 9 6 3 3 100.0 3 None
RS01282 Low 2.4 5 98 21 17 10 3 30.0 3 None
RS01289 Low 2.7 2 35 11 8 5 4 80.0 3 None
RS01274 Low 2.9 3 22 12 9 6 4 66.7 3 NRAS Q61R 42.6%
RS00866 Medium 6.3 7 24 11 8 5 5 100.0 3 NRAS Q61H 72.1%
PIK3CA H1047R 12.4%
RS00860 Medium 6.5 7 19 7 4 3 3 100.0 3 None
RS01294 Medium 6.6 8 8 3 3 3 3 100.0 3 None
RS00875 Medium 6.7 5 17 6 3 2 1 50.0 1 None
RS00855 Medium 6.8 11 16 8 5 3 3 100.0 2 KRAS G12D 37.8%
RS00876 High 16.5 12 15 6 4 4 3 75.0 2 PIK3CA H1047R 43.6%
RS01291 High 16.9 13 18 9 6 3 3 100.0 3 None
RS00871 High 17.8 16 9 4 2 2 2 100.0 2 None
RS00873 High 19.5 10 14 6 3 3 3 100.0 3 None
RS00857 High 20.5 13 15 5 4 4 4 100.0 3 KRAS G12V 29.8%
RS00877 High 23.9 20 12 7 4 4 4 100.0 3 KRAS G12S 48.0%
aTo ensure maximum relevance in the final results, only variants with >5% mean allele frequency from AmpliSeq NGS were evaluated for the calculation of true positives, and systemic variants in the PIK3CA gene were
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modifications introduced by the fixation/embedding
process and thus behaves as a ‘poor man’s’ structural
probe that can segregate the highest and lowest quality
DNA samples relative to PCR amplification (Figure 2).
However, this assay is not capable of differentiating among
lower quality FFPE DNA templates (that is, QFI <3 to
6%), nor can it prescribe specific adjustments in DNA in-
put that may help offset the deleterious effects of poor
functional quality. In fact, the number of variants called in
AmpliSeq NGS was inflated more than 7-fold for the 5
lowest quality FFPE DNA samples in our 44 sample subset
when stratified by QFI (median 222 variants) compared to
Qubit (median 31 variants). Thus, QFI-PCR, but not
Qubit, identified the lowest quality samples at the level of
NGS variant calls. Moreover, correlation between QFI-
PCR and Qubit by template ‘functionality’ for these sam-
ples was poor (R = 0.30). Although a comprehensive un-
derstanding of the molecular features of the binding of
this particular dye to DNA is lacking, the binding site for
similar dyes is only two to four nucleotides [24]. One ex-
planation for this observation is that the lowest quality
FFPE samples contain DNA fragments that are receptive
to dye binding and fluorescent signal enhancement, but
that these samples are poorly amplified by PCR. This is a
critical insight that must be accommodated when the
downstream assay is based on PCR enrichment, as it is for
many targeted NGS assays.
In contrast, we find that the third method, QFI-PCR,
is well suited to profile FFPE DNA intended for targeted
amplification prior to NGS. First, it is logical to design a
quality control with the same methodology that is used
for targeted enrichment. For this reason, we designed
the target amplification region of QFI-PCR to match the
median amplicon size produced by the AmpliSeq Cancer
Panel multiplex PCR. Second, QFI-PCR offers absolute
quantification that can be used independent of other
methods to calculate a minimum copy number input to
satisfy downstream assay requirements. Third, the assay
is sensitive to PCR inhibitors, and thus can predict po-
tentially poor performance in library enrichment due to
extraction contaminants. QFI-PCR respects that high
template quality is not the sole sample-level variable
that drives successful library preparation. Lastly, the
assay is cost-effective, high throughput, and leverages
a ubiquitous install base of real-time thermal cyclers
that can facilitate adoption by research and clinical
laboratories.
It is important to note that the utility of QFI-PCR de-
pends on the use of a genomic locus that is unaffected
by tumor ploidy such that the measured copy number in
FFPE DNA reflects the functional quality of the DNA
specimen and not a separate process. We selected a re-
gion in the TBP gene since this gene was reported to beunchanged in copy number in >98% of TCGA samples
from the cancers investigated in this study. Caution is
warranted for use of this locus in neoplasms such as ad-
enoid cystic carcinomas that have a high rate of TBP
amplification or deletion. In these cases, other genes
such as FTH1 may be targeted instead. Alternatively, a
single multiplex assay that includes both TBP and FTH1
loci may be useful.
Importantly, the results of QFI-PCR can be used to
calculate the minimum amount of sample input for
targeted PCR enrichment by measuring the percentage
of DNA templates that are competent for PCR amplifica-
tion. This insight can reduce the risk of false positives and
false negatives in variant calling using both laboratory-
developed and commercially available procedures for en-
richment and subsequent NGS. This conclusion is evinced
in Figures 3 and 4, and Table 1, which demonstrate that:
i) false negatives and inaccurate mutation fractions can be
rescued by increases in DNA input that are guided by the
QFI; and ii) a commonly used commercial method for the
multiplexed PCR enrichment of cancer genes can produce
an overwhelming number of false positives if the ‘func-
tional’ DNA copy number is unacceptably low. As a result,
the integration of a pre-analytical step based on QFI-PCR
offers a much improved approach to ensure accuracy in
NGS data interpretations. This advance is particularly
timely since ‘benchtop’ NGS instrument placements now
number in the thousands and many solid tumor tests
that are currently performed can (and are) being rapidly
supplanted by PCR-based targeted NGS assays.
Our results have important implications not only
for the evaluation of FFPE DNA prior to NGS, but
also for other assays that rely on PCR amplification.
Rigorous and quantitative characterization of DNA-
poor samples is essential to ensure that results are
generated from sufficient copies of functional DNA
templates, interpreted with consideration of DNA
quality, and can support reliable mutation calls. The
consequences of a misguided diagnostic decision
based on sequencing results from inadequate amplifi-
cation of DNA template are serious and could lead to
inappropriate patient treatment by failing to identify
an actionable mutation or prescribing the wrong
treatment based on a false positive result. Such errors
may also undermine retrospective biomarker associ-
ation studies relevant to cancer drug development. To
this point, we observed that 75% of the false positives
reported in Table 1 were C>T or G>A transition mu-
tations. Repair of FFPE DNA with uracil DNA
glycosylase has recently been reported to reduce the
incidence of such artifactual mutations [25,26] and
other potentially restorative methods for treating
FFPE DNA [27] have been described. These ap-
proaches may be particularly beneficial for low quality
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sensitivity for variant detection to capture a broader
group of clinically relevant mutations, such as those en-
countered in early stage drug resistance [28,29]. In addition,
we note that quantitative sample characterization is re-
quired for the accurate determination of the mutational
load in a tumor, which may have therapeutic value [30]. It
is not surprising, then, that confirmation testing is an indis-
pensable component of existing clinical NGS recommenda-
tions to guard the accuracy of variant calls [23]. We suggest
that quantitative FFPE sample characterization using
threshold-based metrics such as the QFI can improve the
cost, efficiency, and accuracy of confirmation, and help de-
risk the final clinical report. Although FFPE DNA quality
can vary considerably across cohorts, the concerns are most
acute with the lowest quality specimens. In this study, the
median QFI was less than 7% for each of the three collec-
tion cohorts, and across all 6 of the tissue types tested
(colon, lung, skin, ovary, breast, and thyroid). In fact, nearly
half (79/165, 48%) of the 165 FFPE samples in our cohort
had a QFI of <3%.
Conclusions
We recommend routine, functional characterization of
FFPE tumor DNA samples prior to PCR-based targeted
NGS, particularly when the goal is low-level mutation
detection in heterogeneous cancer samples. Although a
correlation was observed in the ‘functional’ DNA frac-
tion comparing QFI-PCR and the fluorescence-based
Qubit assay, this correlation was limited to compara-
tively high quality FFPE samples. That said, the Qubit
assay is clearly superior to spectrophotometry for the as-
sessment of template suitability in PCR, and can provide
specificity to identify those samples that are most likely
to provide high performance NGS results. What this
dye-binding assay cannot do, however, is reliably pin-
point the poorest quality samples, or guide changes in
procedure that can help offset the negative impact on
NGS calls. Without this guidance, many lower quality
FFPE DNA samples that may be well accommodated in
targeted NGS might otherwise be eliminated for testing.
For this reason, we advocate the utility of QFI-PCR,
which provides absolute template quantification that is
responsive to the minimum library complexity required
for accurate NGS results. The actual number of func-
tional copies needed for an NGS assay depends on the
target detection sensitivity; for example, if at least 10 ng
of DNA is required to detect a 5% mutant in a sample
with a 6.6% QFI, then twice as much DNA (and thus
twice the template copy number) is needed to detect a
5% mutant in a sample with a 3.3% QFI. By offering a
quantitative foundation to define pre-analytical, sample-
specific molecular variables, assess template complexity,
and inform input corrections that can help guard againsterroneous mutation calls, QFI-PCR offers a much needed
tool to help meet the challenge of accurate NGS clinical
testing of FFPE tumor biopsies.
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